On Monday, Insulet got an upgrade for its IBD SmartSelect Composite Rating from 93 to 97.
The new score means the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The market's biggest winners often have a 95 or higher grade in the early stages of a new price run, so that's an important benchmark to look for when looking for the best stocks to buy and watch.
Insulet has now climbed above a proper buy zone after breaking out from a 243.98 entry in a flat base.
Discover The 3 Keys To Successful Stock Investing
The stock sports a 99 EPS Rating, which means its recent quarterly and annual earnings growth tops 99% of all stocks.
Its Accumulation/Distribution Rating of A- shows heavy buying by institutional investors over the last 13 weeks.
The company reported a 27% EPS gain for Q3. Top line growth increased 26%, up from 23% in the prior quarter. That marks one quarter of rising revenue gains.
Insulet holds the No. 2 rank among its peers in the Medical-Products industry group. LeMaitre Vascular is the top-ranked stock within the group.
